Status:
TERMINATED
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Conditions:
Thyroid Carcinoma
Radioactive Iodine Level
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to explore whether administration of preservative free artificial tears will decrease the level of detectable radioiodine in the tears and nasolacrimal duct system of pati...
Detailed Description
Primary Objective: \- To assess whether use of preservative free artificial tears following radioactive iodine administration will lower the level of radioactive iodine in the tears of patients treat...
Eligibility Criteria
Inclusion
- Radio-iodine therapy for thyroid cancer
- Radioiodine therapy ≥100mCi
- Patient wears soft contacts on both eyes
Exclusion
- Use of eye drops, other than artificial tears
- History of periocular trauma with tear duct involvement/lacrimal gland trauma
- History of lacrimal drainage disease: canaliculitis, dacryocystitis
- Prior radiotherapy
- Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)
- Medical conditions that predispose to NLD stenosis
- Sarcoid
- Granulomatosis with polyangiitis
- Chronic lymphocytic leukemia
Key Trial Info
Start Date :
October 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 25 2023
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04327999
Start Date
October 5 2020
End Date
September 25 2023
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232